, British HIV Association guidelines for the treatment of HIV-1 infected adults with antiretroviral therapy, BG Gazzard on behalf of the BHIVA Treatment Guidelines Writing Group, pp.563-608, 2008.

H. Günthard, J. Aberg, J. Eron, J. Hoy, A. Telenti et al., Antiretroviral Treatment of Adult HIV Infection, JAMA, vol.312, issue.4, pp.410-435, 2014.
DOI : 10.1001/jama.2014.8722

C. Delaugerre, J. Ghosn, J. Lacombe, G. Pialoux, L. Cuzin et al., Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access, Clinical Infectious Diseases, vol.25, issue.8, pp.436-72, 2015.
DOI : 10.1056/NEJMoa0708975

R. Lodwick, D. Costagliola, P. Reiss, and C. Torti, Triple Class Virologic Failure in HIV-Infected Individuals Undergoing Antiretroviral Therapy for up to 10 years, Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), pp.410-419, 2010.

. Group, F. Nakagawa, R. Lodwick, D. Costagliola, and A. Van-sighem, PLATO II) project team; Collaboration of Calendar time trends in the incidence and prevalence of tripleclass virologic falure in antiretroviral drug-experienced people with hiv in europe, Pursuing Later Treatment Options II, pp.294-303, 2012.

. Group, D. Costagliola, R. Lodwick, and B. Ledergerber, Pursuing Later Treatment Option II (PLATO II) project team Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug class: a cohort study, Observational HIV Epidemiological Research Europe (COHERE) Lancet Infect Dis, vol.12, pp.119-146, 2012.

M. Mary-krause, S. Grabar, L. Lièvre, S. Abgrall, E. Billaud et al., Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4), International Journal of Epidemiology, vol.134, issue.6, pp.1425-1461, 2014.
DOI : 10.1017/S095026880600639X

L. Bracciale, D. Giambenedetto, S. Colafigli, M. , L. Torre et al., Virological Suppression Reduces Clinical Progression in Patients with Multiclass-Resistant HIV Type 1, AIDS Research and Human Retroviruses, vol.25, issue.3, pp.261-268, 2009.
DOI : 10.1089/aid.2008.0136

C. Katlama, B. Clotet, A. Mills, B. Trottier, J. Molina et al., Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials, Antiviral Therapy, vol.15, issue.7, pp.1045-52, 2010.
DOI : 10.3851/IMP1662

C. Allavena, C. Katlama, L. Cotte, P. Roger, P. Delobel et al., Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients, Infectious Diseases, vol.9, issue.4, pp.392-400, 2016.
DOI : 10.3851/IMP2344

C. Fagard, C. Colin, C. Charpentier, A. Rami, C. Jacomet et al., Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.59, issue.5, pp.489-93, 2012.
DOI : 10.1097/QAI.0b013e31824bb720
URL : https://hal.archives-ouvertes.fr/hal-00875207

J. Vingerhoets, V. Calvez, P. Flandre, A. Marcelin, F. Ceccherini-silberstein et al., Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data, HIV Medicine, vol.53, issue.5, pp.297-306, 2015.
DOI : 10.1089/aid.2010.0283

J. Nachega, J. Parienti, O. Uthman, R. Gross, D. Dowdy et al., Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials, Clinical Infectious Diseases, vol.29, issue.Suppl 1, pp.1297-307, 2014.
DOI : 10.1016/S1473-3099(13)70007-0